Home Top Stories Nigeria must bridge research, industry gap to deliver affordable health innovations –...

Nigeria must bridge research, industry gap to deliver affordable health innovations – Ilomuanya

0
27

 

Professor Margaret Ilomuanya

Professor Margaret Ilomuanya of the Department of Pharmaceutics and Pharmaceutical Technology, University of Lagos, has called for stronger collaboration among universities, industry, government and development agencies to ensure that promising health innovations developed by Nigerian researchers are translated into affordable products capable of improving health outcomes across Africa. She made this call in an exclusive interview with Pharmanewsonline.

Ilomuanya, whose research interests include pharmaceutical formulation and drug delivery systems, said her team was making progress towards translating innovations in wound healing and non-hormonal contraception into products that could eventually become accessible to patients. She, however, noted that the journey from successful laboratory research to commercially available health products remained long and uncertain, particularly because of the persistent funding and infrastructure challenges confronting translational research in Nigeria.

“We are actually close to translating some of our innovations for both wound healing and non-hormonal contraception into affordable products,” she said, adding, however, that the meaning of “close” in scientific innovation was relative. According to her, successful proof-of-concept studies have already established the scientific basis for the innovations, while preclinical studies are underway.

The professor explained that the next stages of development would require sustained and strategic investment to prevent promising scientific discoveries from falling into what is often described as the “innovation valley of death”, the difficult gap between early-stage research and the successful development, commercialisation and adoption of a product.

She said many potentially transformative discoveries emerging from African universities and research institutions struggle to progress beyond the laboratory because researchers often lack the funding, industrial partnerships, regulatory support and manufacturing capacity required to take an innovation through preclinical and clinical development to the market.

Ilomuanya expressed optimism that stronger partnerships among universities, pharmaceutical manufacturers, government institutions and development agencies could help overcome these barriers and accelerate the translation of locally generated knowledge into practical health solutions.

“With stronger partnerships between universities, industry, government and development agencies, some of these innovations could reach clinical adoption within the foreseeable future and contribute meaningfully to improving health outcomes across the continent,” she said.

Beyond the development of individual products, she argued that Nigeria must create a stronger policy and industrial environment capable of supporting pharmaceutical innovation from the research stage to commercial production. According to her, the government has a critical responsibility to provide targeted incentives for pharmaceutical manufacturing, strengthen intellectual property protection and expand funding mechanisms specifically designed to support translational research and technology transfer.

She also called on universities to deepen their engagement with industry and develop entrepreneurial programmes that would enable researchers to better understand the commercial dimensions of innovation. Such programmes, she said, could help academics and scientists think beyond publication and laboratory success towards product development, manufacturing, market access and long-term sustainability.

Ilomuanya identified facilities such as the MED-AFRICA Good Manufacturing Practice laboratory as important interventions in efforts to close the gap between academic research and industrial production. She said such facilities provide researchers with opportunities to move promising discoveries closer to the standards and processes required for pharmaceutical manufacturing.

If Nigeria succeeds in aligning its research priorities with the needs of industry, investing in manufacturing infrastructure and creating an enabling policy environment, Ilomuanya believes the country could substantially reduce its dependence on imported medicines and health technologies.

Such a strategy, she added, would not only strengthen Nigeria’s pharmaceutical self-reliance but could also position the country to build a globally competitive pharmaceutical sector driven by local research, innovation and manufacturing capacity.

LEAVE A REPLY

Please enter your comment!
Please enter your name here